The expression of both human lymphocyte antigen (HLA) class I– and HLA class II–related genes was significantly up-regulated in tumor clusters post-iNK treatment (Fig. 7I), which contributed to the allograft rejection pathway enrichment score, suggesting that tumor cells may regulate iNK cell activity through the major histocompatibility complex (MHC) molecules (25, 26). The gene discussed is HLA-C; the disease is neoplasm.